Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Lexeo Therapeutics (LXEO) Change in Accured Expenses (2022 - 2026)

Lexeo Therapeutics' Change in Accured Expenses history spans 2 years, with the latest figure at -$2.1 million for Q4 2023.

On a quarterly basis, Change in Accured Expenses fell 133.48% to -$2.1 million in Q4 2023 year-over-year; TTM through Dec 2023 was $2.1 million, a N/A change, with the full-year FY2025 number at -$4.4 million, down 232.02% from a year prior.
Change in Accured Expenses hit -$2.1 million in Q4 2023 for Lexeo Therapeutics, down from $4.8 million in the prior quarter.
Over the last five years, Change in Accured Expenses for LXEO hit a ceiling of $4.8 million in Q3 2023 and a floor of -$2.1 million in Q4 2023.